-
Mashup Score: 2
Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. Here, we treated 13 CNSL patients with ASCT sequential CD19/22 CAR T-cell infusion and simultaneously evaluated the clinical efficacy and toxicity. The…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 20Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies - Blood Cancer Journal - 3 year(s) ago
Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody–drug conjugates,…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @BloodCancerJnl: Management of Classical Hodgkin Lymphoma. #BCJ #OpenAccess @Razan_Mohty @Mohty_EBMT https://t.co/PPFszEU9Se https://t…
-
-
Mashup Score: 0The Stem Cell Transplant Daily - 3 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Stem Cell Transplant Daily! https://t.co/EJiJL9cXS2 Thanks to @Myeloma_Doc @VincentRK #bcj #openaccess
-
-
Mashup Score: 17Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies - Blood Cancer Journal - 3 year(s) ago
Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody–drug conjugates,…
Source: Blood Cancer JournalCategories: Latest Headlines, Oncologists2Tweet-
RT @BloodCancerJnl: Management of Classical Hodgkin Lymphoma. #BCJ #OpenAccess @Razan_Mohty @Mohty_EBMT https://t.co/PPFszEU9Se https://t…
-
-
Mashup Score: 3Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies - Blood Cancer Journal - 3 year(s) ago
Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody–drug conjugates,…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @BloodCancerJnl: Management of Classical Hodgkin Lymphoma. #BCJ #OpenAccess @Razan_Mohty @Mohty_EBMT https://t.co/PPFszEU9Se https://t…
-
-
Mashup Score: 1Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells - Blood Cancer Journal - 3 year(s) ago
There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers, altering gene-expressions and inducing differentiation and lethality in AML and (MPN) sAML cells….
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Superior efficacy of co-targeting #GFI1/#KDM1A & #BRD4 vs AML & post-MPN secondary AML cells | #BCJ #OpenAccess Dr Bhalla et al @JoeKhouryMD @TapKadia @doctorpemm @DrKTakahashi @Daver_Leukemia #MPNSM #leusm https://t.co/pFJz7tRdp7
-
-
Mashup Score: 3
Global spending on prescription drugs in 2020 is expected to be ~$1.3 trillion; the United States alone will spend ~$350 billion1. These high spending rates are expected to increase at a rate of 3–6% annually worldwide. The magnitude of increase is even more alarming for cancer treatments that account for a large proportion of prescription drug costs. In 2018, global spending on cancer treatments…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
And also in this article. #BCJ https://t.co/OLjNeK0dMp https://t.co/U0jRWuCRMB
-
-
Mashup Score: 3
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC) that infiltrate peripheral tissues and result in detrimental end-organ damage. Disease presentation is rather vague, and the hallmark of…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Comprehensive Review of AL amyloidosis: some practical recommendations [May 18, 2021] @rjalhamed et al. @Mohty_EBMT #BCJ https://t.co/M8IGaf0RV7 #OpenAccess #amyloidosis HT @VincentRK
-
-
Mashup Score: 0Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) - 3 year(s) ago
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, male-predominant hematologic malignancy with poor outcomes and with just one recently approved agent (tagraxofusp). It is characterized by the abnormal proliferation of precursor plasmacytoid dendritic cells (pDCs) with morphologic and molecular similarities to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)/chronic…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
➡️ Features of non-activation dendritic state & immune deficiency in #BPDCN | Blood Cancer Journal #BCJ || Dr Hannah Beird @Malfayez7 @JoeKhouryMD & @doctorpemm || #OpenAccess @VincentRK | #CD123 #TET2 #Eotaxin #RANTES https://t.co/5LHIRQzkng
-
-
Mashup Score: 6Acute promyelocytic leukemia current treatment algorithms - 3 year(s) ago
In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” characterized with a severe bleeding tendency. APL, accounting for 10–15% of the newly diagnosed AML cases, results from a balanced translocation, t(15;17) (q22;q12-21), which leads to the fusion of the…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Acute Promyelocytic Leukemia Current Treatment Algorithm. #BCJ Blood Cancer Journal. #OpenAccess @DrHKantarjian @musayilmaz54 @fravandi1 @MDAndersonNews https://t.co/u9O85SBgfv https://t.co/FxHzjyt6Zr
-
RT @BloodCancerJnl: Novel CAR-T therapy for patients with central nervous system lymphoma. #BCJ #OpenAccess https://t.co/vDddZBsovD